Adela Serrano-Herrera ¹ , Cristina Rodríguez-Martínez ¹ , Paula Domingo-López ¹ , Alberto Girona-Torres ¹ , Pablo Sola- Montijano1, Javier Domingo-López ¹
1 Student of the BSc in Medicine at the University of Granada (UGR)

TRANSLATED BY:

María García-Navarro ² , Natalia Morata-Garrido ² , Gavin Darroch ² , Jesús Sánchez-Rodríguez ² , Begoña Martín- Vázquez ² , Carmen Salmerón-Borja ³
2 Student of the MA in Professional Translation at the University of Granada (UGR)
3 Student of the BA in Translation and Interpreting at the University of Granada (UGR)


Prostate cancer accounts for one-third of new cases of cancer per year, and is now the most frequent type of cancer in men. Recent data suggest that diabetic patients who take metformin, the drug most commonly used in type 2 diabetes, have a lower incidence of certain cancers, such as prostate cancer. Numerous studies have examined the antineoplastic potential of metformin, although its mechanisms are not yet fully understood and the data obtained are ambiguous. This review summarizes the information regarding the effects of metformin on prostate cancer cells, highlighting some of the mechanisms of action through which this drug may act. It also analyzes some conflicting findings regarding the effects of metformin on
patients with different metabolic and pharmacological profiles. After comparing the data, we suggest that metformin could play an important role in the management of prostate cancer in the future, both in monotherapy and combined therapy. At this stage, however, it is still necessary to carry out more effective/ extensive clinical trials to confirm its efficacy.

Keywords: metformin, cancer, prostate, diabetes, AMPK, androgen deprivation therapy (ADT).



Descargar “8.2 – amu – pdi – The Frontiers of Metformin From Diabetes to Prostate Cancer” 8.2-amu-pdi-The-Frontiers-of-Metformin-From-Diabetes-to-Prostate-Cancer.pdf – Descargado 34 veces – 471 KB